SCLX

Scilex Holding Company NASDAQ Listed Mar 5, 2021

Healthcare ·Drug Manufacturers - General ·US · scilexholding.com

$8.04

Mkt Cap $68.3M

52w Low $3.92 13.6% of range 52w High $34.27

50d MA $7.76 200d MA $14.09

P/E (TTM) -0.3x

EV/EBITDA -1.0x

P/B —

Debt/Equity -0.6x

ROE 180.0%

P/FCF 36.6x

RSI (14) —

ATR (14) —

Beta 1.42

50d MA $7.76

200d MA $14.09

Avg Volume 42.8K

Scilex Holding Company, a biopharmaceutical company, focuses on developing and commercializing non-opioid management products for the treatment of acute and chronic pain. Its commercial product is ZTlido 1.8%, a prescription lidocaine topical product for the relief of neuropathic pain related with post-herpetic neuralgia, which is a form of post-shingles nerve pain. It also offers SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trail for the treatment of low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

SIC Code

2836

CIK (SEC)

1820190

Phone

650-516-4310

960 San Antonio Road · Palo Alto, CA 94303 · US

Date	Time	Est	Rptd	Surp	Base	Gap%	D1%	D2%	D3%	D4%	D5%	Guide ▲★
Apr 10, 2026	AMC	-0.47	-4.60	-878.7%	6.80	-4.4%	-12.4%	-0.5%	+6.2%	+4.6%	+4.7%	—
Nov 14, 2025	AMC	-0.47	-22.17	-4617.0%	17.69	-4.0%	-12.3%	+5.5%	+4.9%	+10.3%	+18.8%	—
Aug 13, 2025	AMC	-0.41	-7.42	-1709.8%	21.00	+4.3%	-17.3%	+4.1%	+7.2%	-7.3%	-2.2%	—
May 14, 2025	AMC	-4.20	-2.26	+46.2%	4.47	-3.4%	-7.8%	+2.2%	+11.6%	+6.4%	-5.2%	—
Mar 31, 2025	AMC	-0.10	-0.25	-150.0%	8.70	+5.4%	-4.5%	+25.3%	-4.3%	-9.3%	-3.7%	—
Jan 17, 2025	AMC	-0.17	-6.29	-3600.0%	15.72	+0.4%	-5.8%	+4.0%	-2.3%	+2.4%	+4.5%	—
Aug 13, 2024	AMC	-6.99	-6.29	+10.0%	45.85	+3.8%	-4.6%	-0.8%	-0.8%	+3.3%	-0.8%	—
May 13, 2024	AMC	-4.20	-9.09	-116.4%	28.17	+1.3%	-0.6%	+2.3%	+6.3%	+3.4%	+34.4%	—
Mar 11, 2024	AMC	-7.34	-8.74	-19.1%	49.00	+0.0%	-5.7%	+0.8%	+4.5%	-1.4%	+0.0%	—
Nov 14, 2023	AMC	-5.94	-22.03	-270.9%	43.05	+3.3%	+2.4%	-15.1%	+0.0%	+2.8%	-13.8%	—
Aug 11, 2023	AMC	—	-5.59	—	139.65	+2.0%	-8.8%	-6.5%	+16.3%	+1.3%	-11.5%	—
May 12, 2023	AMC	—	-0.22	—	189.35	+1.3%	+22.9%	+0.8%	+3.7%	-0.7%	+3.5%	—

Date	Firm	Action	Grade	Target	Base	Open	Gap%	D1%	D2%	D3%	D4%	D5%
Apr 11	D. Boral Capital	Downgrade	Buy → Hold	—	$8.75	$6.97	-20.3%	-21.6%	-3.8%	+4.8%	-11.6%	-1.6%
Apr 2	D. Boral Capital	Maintains	Buy → Buy	—	$8.31	$8.23	-1.0%	+25.3%	-4.3%	-9.3%	-3.7%	-0.7%
Feb 28	D. Boral Capital	Maintains	Buy → Buy	—	$7.98	$8.02	+0.5%	+3.5%	+23.5%	+3.1%	+3.1%	+4.5%
Oct 21	HC Wainwright & Co.	Maintains	Buy → Buy	—	$33.95	$34.48	+1.6%	+1.0%	-1.0%	-5.8%	-2.3%	-3.5%
Jun 17	HC Wainwright & Co.	Maintains	Buy → Buy	—	$56.35	$59.85	+6.2%	+33.5%	-14.9%	+7.1%	-10.7%	+2.3%
Jun 11	HC Wainwright & Co.	Maintains	Buy → Buy	—	$39.20	$40.25	+2.7%	+18.8%	+8.3%	+3.5%	+8.1%	+33.5%
May 23	HC Wainwright & Co.	Maintains	Buy → Buy	—	$40.25	$39.20	-2.6%	-5.2%	+3.7%	-4.4%	+5.6%	-2.6%
May 3	HC Wainwright & Co.	Maintains	Buy → Buy	—	$29.69	$30.87	+4.0%	+1.4%	+0.6%	+6.0%	-7.7%	-2.0%
Dec 4	HC Wainwright & Co.	Maintains	Buy → Buy	—	$47.25	$48.30	+2.2%	-3.7%	-9.2%	-3.4%	-4.4%	+0.9%

Data updated apr 27, 2026 12:26am · Source: massive.com